223 related articles for article (PubMed ID: 25782687)
1. New challenges in kidney cancer management: integration of surgery and novel therapies.
Puente Vázquez J; Alonso Gordoa T; Moreno J; Poma L; Diaz Rubio E; Gomez A; Blazquez J; Gonzalez Larriba JL
Curr Treat Options Oncol; 2015 Mar; 16(3):337. PubMed ID: 25782687
[TBL] [Abstract][Full Text] [Related]
2. Multimodal treatment of advanced renal cancer in 2017.
Mennitto A; Verzoni E; Grassi P; Ratta R; Fucà G; Procopio G
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1395-1402. PubMed ID: 28956645
[TBL] [Abstract][Full Text] [Related]
3. Urologic approaches to metastatic renal cell carcinoma.
Mickisch GH
Onkologie; 2001 Apr; 24(2):122-6. PubMed ID: 11441290
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
Schmitz-Dräger BJ; Jankevicius F; Otto T
Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
[TBL] [Abstract][Full Text] [Related]
6. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Margulis V; Matin SF; Wood CG
Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of renal cell carcinoma. A critical appraisal from a urologist's point of view.
Mickisch GH
Urol Int; 1999; 63(1):16-21. PubMed ID: 10592485
[TBL] [Abstract][Full Text] [Related]
9. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
10. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma.
Spiess PE; Fishman MN
Cancer Control; 2010 Oct; 17(4):269-78. PubMed ID: 20861814
[TBL] [Abstract][Full Text] [Related]
12. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
Ghandour RA; Singla N; Margulis V
Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
[TBL] [Abstract][Full Text] [Related]
13. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
14. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
Chaudhary UB; Hull GW
Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
[TBL] [Abstract][Full Text] [Related]
15. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
Bex A; Horenblas S; de Gast GC
Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis.
Petrelli F; Coinu A; Vavassori I; Cabiddu M; Borgonovo K; Ghilardi M; Lonati V; Barni S
Clin Genitourin Cancer; 2016 Dec; 14(6):465-472. PubMed ID: 27138461
[TBL] [Abstract][Full Text] [Related]
17. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
[TBL] [Abstract][Full Text] [Related]
18. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
20. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E
Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
